Huszno Joanna, Kołosza Zofia, Mrochem-Kwarciak Jolanta, Telka Ewa, Jochymek Bożena, Miszczyk Leszek
Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 44-100 Gliwice, Poland.
Genetic Outpatient Clinic, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 44-100 Gliwice, Poland.
Oncol Lett. 2022 Jul 8;24(3):305. doi: 10.3892/ol.2022.13425. eCollection 2022 Sep.
The aim of the present analysis was to evaluate the platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelets (PLT) and neutrophil level for their prognostic values in patients with prostate cancer who had been treated with radiotherapy. A retrospective analysis of 152 patients who were treated in the Radiotherapy Department at Maria Sklodowska-Curie National Research Institute of Oncology (Gliwice, Poland) between January 2012 and December 2014 was performed. The prognostic value (overall survival; OS) of the pre-treatment PLR, NLR, LMR, PLT, neutrophil level and other laboratory factors such as: leukocyte, lymphocyte, monocyte, hemoglobin, RBC, prostate-specific antigen level (PSA), Gleason score, age, smoking and comorbid condition were assessed using univariate analysis. The cut-off point was determined for NLR as 'elevated' at >4.66, LMR >3.26 and the PLR was considered 'elevated' at >89.6. Median follow-up was 4.9 years. The 5 and 7-year OS rates were 81.5 and 72.2%, respectively. In univariate analysis higher NLR (P=0.007), higher level of PLT (P=0.004), higher level of neutrophils (P=0.013), elevated level of leukocyte (P=0.043) and lymphocyte (P=0.043) were factors significantly associated with decreased OS. No difference was found for PLR (P=0.308) and LMR (P=0.109). The other factor associated with decreased OS were: higher Gleason score (>7; P=0.005), higher PSA level (>20 ng/dl; P=0.0001), smoking (P=0.003) and older age (>70 years; P=0.018). In multivariate analysis, NLR, LMR, leukocyte and RBC were independently associated with prognosis in patients with prostate cancer. Elevated pre-treatment NLR [hazard ratio (HR)=10.83; P=0.001), LMR (HR=3.14; P=0.007) and higher leukocyte level (HR=3.14; P=0.007) were independently associated with increased mortality risk. Overall, pre-treatment NLR, PLR, leukocyte and RBC levels were revealed to be independent prognostic factors.
本分析的目的是评估血小板淋巴细胞比率(PLR)、中性粒细胞淋巴细胞比率(NLR)、淋巴细胞单核细胞比率(LMR)、血小板(PLT)和中性粒细胞水平对接受放疗的前列腺癌患者的预后价值。对2012年1月至2014年12月期间在玛丽亚·斯克洛多夫斯卡-居里国家肿瘤研究所放疗科(波兰格利维采)接受治疗的152例患者进行了回顾性分析。采用单因素分析评估治疗前PLR、NLR、LMR、PLT、中性粒细胞水平及其他实验室因素(如白细胞、淋巴细胞、单核细胞、血红蛋白、红细胞、前列腺特异性抗原水平(PSA)、Gleason评分、年龄、吸烟和合并症)的预后价值(总生存期;OS)。确定NLR的截断点为>4.66时“升高”,LMR>3.26时“升高”,PLR>89.6时被认为“升高”。中位随访时间为4.9年。5年和7年总生存率分别为81.5%和72.2%。在单因素分析中,较高的NLR(P=0.007)、较高的PLT水平(P=0.004)、较高的中性粒细胞水平(P=0.013)、升高的白细胞水平(P=0.043)和淋巴细胞水平(P=0.043)是与总生存期降低显著相关的因素。PLR(P=0.308)和LMR(P=0.109)未发现差异。与总生存期降低相关的其他因素包括:较高的Gleason评分(>7;P=0.005)、较高的PSA水平(>20 ng/dl;P=0.0001)、吸烟(P=0.003)和老年(>70岁;P=0.018)。在多因素分析中,NLR、LMR、白细胞和红细胞与前列腺癌患者的预后独立相关。治疗前升高的NLR[风险比(HR)=10.83;P=0.001]、LMR(HR=3.14;P=0.007)和较高的白细胞水平(HR=3.14;P=0.007)与死亡风险增加独立相关。总体而言,治疗前NLR、PLR、白细胞和红细胞水平被揭示为独立的预后因素。